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Introduction
Antithrombin (AT) 1 belongs to the serine protease inhibitor family (serpin) and is by way of inhibition of especially thrombin (T) and activated factor X an important regulator of blood coagulation [1] . A characteristic structural feature of AT and of other members of the serpin family is the five stranded β-sheet A, and the mobile reactive center loop (RCL), which contains the reactive P 1 -P´1 Arg-Ser bond in AT [2] .
Complex formation between a serpin and a protease induces profound structural changes in the inhibitor. An initially formed Michaelis complex is transformed to a covalent acyl ester intermediate between the P 1 residue in the inhibitor and the protease active site serine residue by cleavage of the RCL. The cleaved RCL, with attached protease, is inserted as strand four in β-sheet A with translocation of the protease to the opposite pole of the inhibitor [3] . The inhibitory reaction follows a branched pathway with the final formation of a stable proteaseinhibitor complex as well as a small amount of cleaved inhibitor [4] . The crystal structure of the trypsin-antitrypsin complex reveals that the active site of the protease is distorted, thus precluding cleavage of the acyl bond between the inhibitor and the protease [5] .
In contrast to most other serpins, native AT has the residues at positions P15 and P14 in the so-called hinge region of the RCL inserted into β-sheet A [6] . By heparin binding this region is expelled from sheet A, contributing to an increased flexibility of the exposed RCL [7] . This not only accelerates the rate of protease inhibition but also promotes the pathway leading to cleavage of the acyl intermediate between AT and T. In the presence of heparin about 30 % of the reaction products are cleaved AT as compared to 7 % in the absence of heparin [8, 9] .
A common feature for inhibitory serpins is the stability of the cleaved, loop-inserted form in even 6 M Guanidine-HCl, conditions under which the native serpin is denatured. An alternative stable structure of AT is the so-called latent form (L-AT), in which the RCL has been inserted into β-sheet A without previous cleavage of the reactive P 1 -P´1 bond [10] . A similar conformational variant has been reported for plasminogen activator inhibitor 1, α 1 -antitrypsin and α 1 -antichymotrypsin [11] [12] [13] . Formation of L-AT is induced by incubation of purified native AT at 50-60°C or of plasma at 37°C, which may explain the contamination of commercial AT preparations by L-AT [14, 15] . Both cleaved and latent AT inhibit tumor angiogenesis [16, 17] .
As a result of the drastic conformational changes in the serpin structure, following loop insertion into β-sheet A, new epitopes appear. Monoclonal antibodies (mabs) have been described reacting with such neoepitopes in cleaved free and protease complexed plasminogen activator inhibitor type-1 and typ-2, in C1-inhibitor, and in protein C inhibitor [18] [19] [20] [21] [22] . Protein C inhibitor in complex with activated protein C has been found to be a marker for venous thrombosis [23, 24] .
In the present study we describe a high affinity murine mab, M9, selected to be specific for loop inserted cleaved and latent AT. No binding was observed to native AT. Using M9
together with a second monoclonal antibody against AT, which does not recognize L-AT, we have devised a sandwich assay to measure the plasma concentration of cleaved AT.
Proteins and peptides
Native AT was purified from human plasma as described [25] . Cleaved AT was produced by the incubation of native AT with porcine elastase (Sigma-Aldrich, Stockholm, Sweden) at a 100:1 molar ratio [26] . After 2 h at 37°C, α 1 -antitrypsin was added to inhibit the elastase. The cleaved AT was purified on a 5 ml HiTrap Heparin HP Column (Amersham Biosciences, Uppsala, Sweden), equlibrated with 50 mM Tris, 0.1 M NaCl pH 7.5. A NaCl-gradient of 50 ml (0.1-1 M) eluted cleaved AT at 0.4 M NaCl. L-AT was produced by incubating native AT (10 mg) at 50°C for 72 h in 50 mM Tris, 0.1 M NaCl pH 7.4, containing 20% glycerol [17] .
The L-AT was purified using the same method as for cleaved AT. TAT complexes were formed in 50 mM Tris, 0.1 M NaCl pH 7.4. Native AT (52 nmol) was mixed with 30 nmol T, incubated at room temperature for 4 min after which 20 nmol PPACK (CalbiochemNovabiochem Corporation, La Jolla, CA, USA) was added. TAT was purified on a Heparin
HiTrap column as described above. SDS-PAGE showed one major band corresponding to TAT and two minor bands corresponding to cleaved AT and T. Protein concentrations were determined by amino acid analysis after acid hydrolysis. Prothrombin was purified using a standard procedure [27] . The protein was activated as described [28] .
The RCL-peptide was synthesized on a Milligen 9050 Plus instrument (Perkin-Elmer, Stockholm, Sweden), and purified by reverse-phase HPLC. Insertion of the RCL into native AT was performed, by incubating 6.9 nmol native AT with 690 nmol of a synthetic RCLpeptide at 37°C for 20 h [29] . The RCL-complexed AT (RCL-AT) was then purified on a Heparin HiTrap Sepharose Column. The RCL insertion was confirmed by protein sequencing.
Monoclonal antibodies
Murine mabs were produced as described [22] . Mice were immunized with TAT. To find mabs specific for cleaved AT, an ELISA screening method was used, based upon the formation of complexes between biotinylated bovine activated factor X and AT (BXa-AT) in human heparin plasma. The BXa-AT containing plasma was diluted 1/50 with plasma diluted After 30 min incubation at room temperature followed by washing, 50 µl BXa-AT was added. Mab M27, specific for native and cleaved AT, has been described earlier and mab M38 recognizes all forms of AT [30] .
Affinity chromatography
Mixtures of equal amounts (50 µg) of purified native and latent as well as native and cleaved
AT were applied at a flow rate of 0.5 ml/min to a 1 ml HiTrap Heparin HP Column, equlibrated with 50 mM Tris-HCl, 0.1 M NaCl, pH 7.4 (TBS). The proteins were eluted with a NaCl-gradient (0.1-1.5 M, 25 ml). The absorbance of the effluent was monitored at 280 nm. Blood samples were drawn from 9 patients before and 15 h after administration of a single dose of 40 mg low molecular weight heparin (Klexane®) prior to hip surgery.
Stability of cleaved AT and TAT in citrated and heparinised plasma
Blood from a healthy person was drawn in tubes containing either 0.5 ml 0.129 M Na-citrate or heparin. The tubes were immediately centrifuged at 1500 g for 10 min, after which the plasma was incubated at room temperature. Aliquots were taken after 0, 1, 2, 4, 6, 24, and 52
h and frozen at -70°C. Cleaved AT and TAT were measured as described above.
Other methods

Eu
3+
-DTTA chelate labeling (Wallac) and biotinylation with NHS-LC-biotin (Pierce, Rockford, IL) were performed as described by the manufacturers. SDS-PAGE was carried out using a standard method.
Results
Properties of mab M9 specific for the cleaved and latent forms of AT
The monoclonal antibody, M9, was obtained by immunizing mice with the TAT complex.
The screening procedure was designed to ensure that only mabs specific for the loop-inserted form of the inhibitor were identified. Thus, biotinylated bovine factor Xa was added to human plasma to obtain BXa-AT complexes. The substitution of thrombin for factor Xa in complex with AT ensured that mabs reacting with the protease were not detected. Moreover, due to the large molar excess of free, uncleaved AT in plasma over the forms with the RCL inserted in β-sheet A, only mabs with the desired specificity were identified. Two mabs were selected and one of them, M9, was characterized in detail.
In a first test of the specificity of M9, mixtures of native and cleaved and of native and latent AT were chromatographed on a HiTrap heparin HP column that was eluted with a NaCl gradient (Fig. 1) . The eluate was analyzed for its ability to inhibit thrombin in an amidolytic assay and for its ability to bind to M9 in a sandwich assay as described in Materials and
Methods. Cleaved and latent AT, which have lower affinity for heparin than native AT, eluted in the first peak at about 0.4 M NaCl. They had no thrombin inhibitory activity but both were recognized by M9. Native AT eluted in the second peak at about 0.9 M NaCl. It inhibited thrombin but did not bind M9.
The three forms of AT were also analyzed in competitive binding experiments.
Competition with Eu
3+
-labeled cleaved AT for binding to biotinylated M9 was measured.
Cleaved and latent AT and the TAT complex competed equally well for binding to the mab ( Fig. 2A) . In contrast, native AT had no discernible affinity for the mab. There appeared to be a weak competition with RCL-AT. This type of loop-inserted AT is obtained by incubation with a large molar excess of the synthetic loop at 37°C. However control AT, incubated without RCL, displayed the same degree of competition. We therefore infer that the displacement was due to a conversion of about 1% of the native AT to the latent conformation during the incubation rather than competition by the form with inserted synthetic peptide.
The affinity of different forms of AT for M9 was also studied by surface plasmon resonance using a Biacore 2000 instrument. Binding of different concentrations of AT to the immobilized mab was analyzed using the Biaevaluation 3.0 software package. The K D s of cleaved and latent AT and of the TAT complex were from 0.96 x 10 -9 M to 3.07 x 10 -9 M with the complex having the highest affinity ( Table 1 ). The differences were accounted for by differences in the rate of dissociation. The affinity of the native/stressed form of AT could not be measured as it was too low to give a signal.
Isolation of cleaved/latent AT from plasma using M9
As cleaved/latent AT has been found to contaminate commercial AT concentrates used in clinical medicine we investigated whether the mab could be used to isolate the two species of AT by immunoaffinity chromatography. To that end 5 ml of undiluted citrated plasma was applied to a M9-conjugated Sepharose column and after washing, the bound AT was eluted at a low pH (Fig. 3) . With PabAT as catcher and Eu 
Properties of mab M27, specific for the cleaved and native forms of AT
An assay that measures cleaved AT and utilizes a catcher mab specific for the loop-inserted forms of AT requires that the reporter mab binds to cleaved AT and has no affinity for latent AT. We have previously characterized a monoclonal antibody, mab M27, with these properties [30] . The epitope of this mab involves the sequence Phe-Ile-Arg-Glu-Val-Pro (residues 411-416). The affinity of the mab for latent AT is more than 200-fold lower than it is for cleaved AT making it useful as a reporter mab in a sandwich assay (Fig. 2B) .
A sandwich assay for measurements of cleaved AT in plasma
A sandwich assay for cleaved AT was devised using M9 as catcher mab and Eu
3+
-labeled M27 as reporter mab. Due to the high affinity of the mabs the assay gives linear doseresponse curves (Fig. 4) . 
Generation of cleaved AT in citrated and heparinised plasma
Normal heparinised and citrated plasmas were incubated at room temperature for 52 h and the formation of cleaved AT and TAT was examined. There was no change in the concentration of either cleaved AT or TAT in the citrated plasma within the incubation time. In the heparinised plasma both TAT and cleaved AT increased with time, resulting in an approximal duplication of the concentrations in 52 h (Fig. 7) .
Discussion
Unlike the native form of AT both the cleaved and latent forms have antiangiogenic properties |16,17]. Recently, it was shown by densitometric scanning that both these forms of AT are trace components in human plasma [31] . The latent form has also been found to constitute a significant part of AT preparations that are used therapeutically [14] . Latent AT does not inhibit T or active factor X but forms a non-covalent, inactive dimer with the native form of AT [15] . For these reasons high concentrations of latent AT are linked to an increased risk to develope venous thrombosis [32] .
It is of potential clinical interest to be able to measure both cleaved and latent AT in plasma, for instance, in patients with malignancies and/or with pathologic proteolysis. It is also important to be able to measure these forms of AT in concentrates intended for clinical use. Two methods have been devised to measure cleaved/latent AT. They depend on preanalytic removal of native AT either by thermal or SDS-mediated denaturation, which is followed by ELISA. Both methods presumably measure the sum of the cleaved and latent forms of AT [33, 34] . Therefore, we have developed a sandwich assay that specifically measures cleaved AT without interference from the native or latent forms. The method depends on a very high affinity catcher mab that binds AT with the RCL inserted into β-sheet A, i.e. AT in complex with T/factor Xa as well as the cleaved and latent forms, but has no measurable affinity for the native form. The reporter mab binds cleaved AT but has a ~200-fold lower affinity for the latent form.
The location of the epitope of mab M9 has not been defined. A mab (M36) against protein C inhibitor has properties similar to those of mab M9, i.e. it is specific for the loop-inserted form of the inhibitor [22] . This mab has the epitope in the vicinity of residue P13 of the loop inserted into β-sheet A. It could be induced by insertion of the RCL into β-sheet A of the protein C inhibitor. However, insertion of the corresponding synthetic reactive site loop into β-sheet A of AT did not induce the epitope.
We found the median concentration of cleaved AT in plasma to be 1.3 mg/L. The TAT complex is codetermined, but since its concentration is ~10 3 -fold lower (1.0-4.1 µg/L in adults), it does not pose a problem even in pathological conditions.
The pathway for inhibition of T by AT is branched, leading to complex formation and inhibition of T as well as to cleavage of AT and liberation of active T due to cleavage of the acyl-enzyme intermediate. It has been observed in vitro that TAT formation in the presence of heparin is accompanied by the formation of about 30% of cleaved AT relative to TAT, and that the amount of cleaved AT produced under physiological conditions is independent of the AT/T ratio in the reaction [8, 9] . In vivo, the complex between T and AT is formed under heparinised conditions due to heparin-like substances, which are bound to the surface of capillary endothelial cells [35] . This poses the question whether the cleaved AT in plasma can be accounted for solely by the cleavage of AT that is coupled to complex formation with T, or if there are other sources, for instance AT cleavage mediated by enzyme(s) other than thrombin [33, 36] . In humans the half-life of native AT is ~64 h, whereas the half-lives of cleaved and latent AT have not been determined, nor has that of the TAT complex [37] . In rabbits the half-life of native as well as cleaved and latent AT is 20 h and that of the TAT complex is 18 min [31] . We assume that the three-fold longer half-life of native AT in Elastase might be involved in the production of cleaved AT, as it binds to glycosaminoglycans like AT and has been reported to cleave AT effectively in vitro in the presence of heparin [38] . However, the elastase cleavage of AT is at the Ile390-Ala391 peptide bond, whereas we only have observed the thrombin Arg393-Ser394 cleavage in AT purified from plasma by affinity chromatography utilizing mab M9. The production of cleaved AT in the microvasculature thus exceeds that observed in vitro under heparinised condition and the mechanism is unclear. Values represent the mean value (±SD). 
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